Molecular Insight Pharmaceuticals, Inc. - Amended Statement of Ownership (SC 13G/A)
February 26 2008 - 12:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
60852M104
(CUSIP Number)
December 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o
Rule 13d-1(b)
þ
Rule 13d-1(c)
o
Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
|
|
|
|
CUSIP No.
|
|
60852M104
|
|
Page
|
|
2
|
|
of
|
|
7
|
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
Highland Capital Management, L.P.
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
2,488,692
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
2,488,692
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
2,488,692
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
9.2%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
PN/IA
|
|
|
|
|
|
|
|
|
|
|
|
CUSIP No.
|
|
60852M104
|
|
Page
|
|
3
|
|
of
|
|
7
|
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
Strand Advisors, Inc.
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
Delaware
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
2,488,692
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
2,488,692
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
2,488,692
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
9.2%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
CO/HC
|
|
|
|
|
|
|
|
|
|
|
|
CUSIP No.
|
|
60852M104
|
|
Page
|
|
4
|
|
of
|
|
7
|
|
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
James Dondero
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a)
o
|
|
(b)
o
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
United States
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
NUMBER OF
|
|
2,488,692
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
BENEFICIALLY
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
REPORTING
|
|
|
PERSON
|
|
2,488,692
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
2,488,692
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
o
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
9.2%
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
IN/HC
|
This Amendment No. 1 to Schedule 13G is jointly filed by and on behalf of each reporting person to
amend and/or supplement the Schedule 13G relating to shares of Common Stock of the Issuer filed by
such reporting person with the Securities and Exchange Commission on November 26, 2007 (the
Schedule 13G
). Capitalized terms used and not defined herein shall have the meanings assigned to
such terms in the Schedule 13G. Except as otherwise provided herein, all Items of the Schedule 13G
remain unchanged.
|
|
|
Item 1(a)
|
|
Name of Issuer:
|
Molecular Insight Pharmaceuticals, Inc. (the
Issuer
).
|
|
|
Item 1(b)
|
|
Address of Issuers Principal Executive Offices:
|
160 Second Street, Cambridge, MA 02142.
|
|
|
I
tem 2(a)
|
|
Name of Persons Filing:
|
This statement is filed by and on behalf of: (i) Highland Capital Management, L.P.
(
Highland Capital
); (ii) Strand Advisors, Inc. (
Strand
); and (iii) James D. Dondero
(
Dondero
).
Highland Capital principally serves as an investment adviser and/or manager to other
persons;
Highland Capital may be deemed to beneficially own shares owned and/or held by and/or for the
account of and/or benefit of other persons. Strand serves as the general partner of Highland
Capital; Strand may be deemed to beneficially own shares owned and/or held by and/or for the
account of and/or benefit of Highland Capital. Dondero is the President and a director of Strand;
Dondero may be deemed to beneficially own shares owned and/or held by and/or for the account of
and/or benefit of Strand.
Each of the reporting persons declares that neither the filing of this statement nor
anything herein
shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g)
of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
Each of the reporting persons may be deemed to be a member of a group with respect to
the Issuer
or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the
reporting persons declares that neither the filing of this statement nor anything herein shall be
construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the
Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other
person) as a partnership, limited partnership, syndicate, or other group for the purpose of
acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the
Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or
any securities of the Issuer.
|
|
|
Item 2(b)
|
|
Address of Principal Business Office or, if non Residence:
|
The address of the principal business office of each of the reporting persons is Two Galleria
Tower, 13455 Noel Road, Suite 800, Dallas, Texas 75240.
See Item 4 of each cover page for the respective reporting persons.
|
|
|
Item 2(d)
|
|
Title of Class of Securities:
|
Common Stock, par value $0.01 per share (the
Common Stock
).
60852M104.
|
|
|
Item 3
|
|
Status of Persons Filing.
|
Not applicable.
Page 5 of 7
|
(a)
|
|
Amount Beneficially Owned:
|
|
|
|
|
See Item 9 of each cover page for the respective reporting persons.
|
|
|
(b)
|
|
Percent of Class:
|
|
|
|
|
See Item 11 of each cover page for the respective reporting persons.
|
|
|
(c)
|
|
Number of shares as to which the person has:
|
|
(i)
|
|
Sole power to vote or to direct the vote:
|
|
|
|
|
See Item 5 of each cover page for the respective reporting persons.
|
|
|
(ii)
|
|
Shared power to vote or to direct the vote:
|
|
|
|
|
See Item 6 of each cover page for the respective reporting persons.
|
|
|
(iii)
|
|
Sole power to dispose or to direct the disposition of:
|
|
|
|
|
See Item 7 of each cover page for the respective reporting persons.
|
|
|
(iv)
|
|
Shared power to dispose or to direct the disposition of:
|
|
|
|
|
See Item 8 of each cover page for the respective reporting persons.
|
|
|
|
Item 5
|
|
Ownership of 5% or Less of a Class.
|
Not applicable.
|
|
|
Item 6
|
|
Ownership of More than 5% on Behalf of Another Person.
|
Highland Capital serves as an investment adviser and/or manager to other persons;
Highland
Capital may be deemed to beneficially own shares owned and/or held by and/or for the account and/or
benefit of other persons.
|
|
|
Item 7
|
|
Identification and Classification of the Subsidiary Which Acquired the Security Being
Reported on by the Parent Holding Company or Control Person.
|
Not applicable.
|
|
|
Item 8
|
|
Identification and Classification of Members of the Group.
|
Not applicable.
|
|
|
Item 9
|
|
Notice of Dissolution of Group.
|
Not applicable.
By signing below I certify that, to the best of my knowledge and belief, the securities
referred to
above were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or effect.
Page 6 of 7
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
Date: February 14, 2008
|
|
|
|
|
|
Highland Capital Management, L.P.
By: Strand Advisors, Inc., its general partner
|
|
|
By:
|
/s/ James D. Dondero
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
Strand Advisors, Inc.
|
|
|
By:
|
/s/ James D. Dondero
|
|
|
|
James D. Dondero, President
|
|
|
|
|
|
|
|
James D. Dondero
|
|
|
/s/ James D. Dondero
|
|
|
|
|
|
Page 7 of 7
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From May 2024 to Jun 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jun 2023 to Jun 2024